Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 8/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.54 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | PDE5A | O76074 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL582644 | 0.89 | PDE4B (0.60) | PDE4BGAASMN1; SMN2MAPTADORA1 | |
| SCHEMBL2528129 | 0.88 | PDE4B (0.63) | PDE4BSMN1; SMN2ADORA1NR3C1KMT2A | |
| SCHEMBL17963376 | 0.87 | NR3C1 (0.61) | PDE4BSMN1; SMN2MAPTLMNANPC1 | |
| SCHEMBL1003088 | 0.83 | GAA (0.54) | PDE4BGAASMN1; SMN2MAPTADORA1 | |
| SCHEMBL582528 | 0.83 | PDE4B (0.65) | PDE4BMAPTNR3C1KMT2APDE5A | |
| SCHEMBL12604349 | 0.82 | UCHL1 (0.51) | PDE4BGAASMN1; SMN2MAPTUCHL1 | |
| SCHEMBL17963291 | 0.82 | KMT2A (0.71) | SMN1; SMN2LMNANR3C1KMT2AALDH1A1 | |
| SCHEMBL5260422 | 0.82 | LMNA (0.50) | SMN1; SMN2MAPTADORA1LMNANPC1 | |
| SCHEMBL583328 | 0.82 | GAA (0.74) | PDE4BGAASMN1; SMN2MAPTADORA1 | |
| SCHEMBL4802198 | 0.81 | KMT2A (0.56) | PDE4BGAASMN1; SMN2MAPTUCHL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4186897-A1 | PYRIDINECARBOXAMIDE COMPOUND USEFUL AS PIM KINASE INHIBITOR | Incyte Holdings Corporation (US) | 2023-05-31 | — | — | EP | disclosed |
| EP-4186897-A1 | PYRIDINECARBOXAMIDE COMPOUND USEFUL AS PIM KINASE INHIBITOR | Incyte Holdings Corporation (US) | 2023-05-31 | — | — | EP | disclosed |
| EP-3670506-B1 | THIAZOLECARBOXAMIDES AND PYRIDINECARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | INCYTE HOLDINGS CORP (US) | 2023-01-04 | — | — | EP | disclosed |
| EP-3670506-B1 | THIAZOLECARBOXAMIDES AND PYRIDINECARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | INCYTE HOLDINGS CORP (US) | 2023-01-04 | — | — | EP | disclosed |
| US-11485745-B2 | Amido spirocyclic amide and sulfonamide derivatives | VALO HEALTH, INC. (US) | 2022-11-01 | — | — | US | disclosed |
| US-11229631-B2 | Thiazolecarboxamides and pyridinecarboxamide compounds useful as Pim kinase inhibitors | INCYTE CORPORATION (US) | 2022-01-25 | — | — | US | disclosed |
| US-11229631-B2 | Thiazolecarboxamides and pyridinecarboxamide compounds useful as Pim kinase inhibitors | INCYTE CORPORATION (US) | 2022-01-25 | — | — | US | disclosed |
| US-20210171545-A1 | AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES | VALO HEALTH, INC. | 2021-06-10 | — | — | US | disclosed |
| US-20200405702-A1 | THIAZOLECARBOXAMIDES AND PYRIDINECARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | INCYTE CORPORATION | 2020-12-31 | — | — | US | disclosed |
| US-20200405702-A1 | THIAZOLECARBOXAMIDES AND PYRIDINECARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | INCYTE CORPORATION | 2020-12-31 | — | — | US | disclosed |
| US-20100292196-A1 | PYRAZOLO (3, 4-B) PYRIDINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2010-11-18 | — | — | US | disclosed |
| US-20100048552-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHBITORS | IRM LLC (BM) | 2010-02-25 | — | — | US | disclosed |
| US-20100048552-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHBITORS | IRM LLC (BM) | 2010-02-25 | — | — | US | disclosed |
| WO-2010003025-A1 | BICYCLIC HETEROCYCLES AS MEK KINASE INHIBITORS | GENENTECH, INC. (US) | 2010-01-07 | — | — | WO | disclosed |
| EP-2027123-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-02-25 | — | — | EP | disclosed |
| WO-2008144253-A1 | PROTEIN KINASE INHIBITORS AND METHODS FOR USING THEREOF | IRM LLC (BM) | 2008-11-27 | — | — | WO | disclosed |
| WO-2007134259-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2007-11-22 | — | — | WO | disclosed |
| WO-2007134259-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2007-11-22 | — | — | WO | disclosed |
| EP-1043998-B1 | USE OF PYRAZOLO [3,4-b] PYRIDINE AS CYCLIN DEPENDANT KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2007-03-07 | — | — | EP | disclosed |
| US-6107305-A | Use of pyrazolo [3,4-b] pyridine as cyclin dependent kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048552-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHBITORS | BMX, FYN, FRK | PDE4B 3709/4885GAA 2094/4885SMN1; SMN2 2708/4885 |
| US-20100292196-A1 | PYRAZOLO (3, 4-B) PYRIDINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | PDE3B, PDE4A, PDE3A | PDE4B 5/4885GAA 739/4885SMN1; SMN2 2927/4885 |
| US-20210171545-A1 | AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES | STS, AADAC, SULT2A1 | PDE4B 1995/4885GAA 1153/4885SMN1; SMN2 1264/4885 |
| US-11485745-B2 | Amido spirocyclic amide and sulfonamide derivatives | STS, AADAC, SULT2A1 | PDE4B 1995/4885GAA 1153/4885SMN1; SMN2 1264/4885 |
| US-20200405702-A1 | THIAZOLECARBOXAMIDES AND PYRIDINECARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | PIM2, PIM1, PIM3 | PDE4B 2980/4885GAA 1208/4885SMN1; SMN2 3837/4885 |
| US-11229631-B2 | Thiazolecarboxamides and pyridinecarboxamide compounds useful as Pim kinase inhibitors | PIM2, PIM1, PIM3 | PDE4B 2980/4885GAA 1208/4885SMN1; SMN2 3837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.